ArticleJNCI cancer spectrum2021
Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer.
Article in JNCI cancer spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Trends in stage-specific prostate cancer incidence by neighborhood socioeconomic status.JNCI cancer spectrum · 2025Article
- Integrating Multi-Omics Data to Uncover Prostate Tissue DNA Methylation Biomarkers and Target Genes for Prostate Cancer Risk.Molecular carcinogenesis · 2025Article
- Chronological Trends of PSA Levels at Diagnosis in Population-based Prostate Cancer Data 2004-2021, a Time Period of Drastic Changes in Screening Guidelines: Potential Implications in Prostate Cancer Diagnosis.Journal of registry management · 2025Article
- The global, regional, and national prostate cancer burden and trends from 1990 to 2021, results from the global burden of disease study 2021.Frontiers in public health · 2025Article
- Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019.JNCI cancer spectrum · 2024Article
- Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer.JAMA network open · 2024Article
- Inhibition of orthotopic castration-resistant prostate cancer growth and metastasis in mice by JC VLPs carrying a suicide gene driven by the PSA promoter.Cancer gene therapy · 2024Article
- Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.NEJM evidence · 2022Article
- How Did CNBSS Influence Guidelines for So Long and What Can That Teach Us?Current oncology (Toronto, Ont.) · 2022Article
- Article
- Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019.Frontiers in public health · 2022Article
- Geographic disparities in Saskatchewan prostate cancer incidence and its association with physician density: analysis using Bayesian models.BMC cancer · 2021Article
- Learning from prostate cancer statistics.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Recent studies show decreasing prostate-specific antigen utilization and increasing incidence of metastatic prostate cancer in the United States after national recommendations against screening in 2012. Yet, whether the increasing incidence of metastatic prostate cancer is consistent in magnitude with the expected impact of decreased screening is unknown. We compared observed incidence of metastatic prostate cancer from the Surveillance, Epidemiology, and End Results program and published effects of continued historical screening and discontinued screening starting in 2013 projected by 2 models of disease natural history, screening, and diagnosis. The observed rate of new metastatic prostate cancer cases in 2017 was 44%-60% of the projected increase under discontinued screening relative to continued screening. Thus, the observed increase in incident metastatic prostate cancer is consistent with the expected impact of reduced screening. Although this comparison does not establish a causal relationship, it highlights the plausible role of decreased screening in the observed trend.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.